The study using KDM6A-knockout bladder cancer cells and patient-derived xenograft model suggested that EZH2 (enhancer of zeste homolog 2, H3K27 methylase) inhibition is a potential therapeutic target for bladder cancer with the mutations [40]. This evidence concerns the gene EZH2 and urinary bladder carcinoma.